摘要 |
The present invention relates to an alpha 2-plasmin inhibitor comprising as the main ingredient a compound selected from the group consisting of (1) through (4) below: (1) a compound represented by the following general formula [I] and a physiologically acceptable acid addition salt thereof as well as a quaternary salt thereof, (2) nojirimycin and a physiologically acceptable acid addition salt thereof; (3) 1,4-bis(3-moranolino-1-propenyl)benzene and a physiologically acceptable acid addition salt thereof; and, (4) castanospermine; <CHEM> wherein R<1> represents hydrogen, an alkyl, a carboxyalkyl, an alkyloxycarbonylalkyl, a hydroxyalkyl, a cycloalkylalkyl, an arylalkyl, an aryloxyalkyl, an alkenyl, or a substituted or unsubstituted arylalkenyl, as well as to an urokinase secretion accelerator and a thrombolytic composition comprising as the main ingredient a compound selected from the group consisting of (1) through (4) below: (1) a compound represented by the following general formula [II] and a physiologically acceptable acid addition salt thereof as well as a quaternary salt thereof, (2) nojirimycin and a physiologically acceptable acid addition salt thereof; (3) 1,4-bis(3-moranolino-1-propenyl)benzene and a physiologically acceptable acid addition salt thereof; and, (4) castanospermine; <CHEM> wherein R<2> represents hydrogen, alkyl, carboxyalkyl, alkyloxycarbonylalkyl, hydroxyalkyl, cycloalkylalkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryloxyalkyl, alkenyl, hydroxyalkenyl, substituted or unsubstituted arylalkenyl, aryloxyalkenyl or alkylcarbamoylalkyl. d |